ライフサイエンスコーパス: falciparum malaria

1 malaria and 10 to 16 hours in those with P. falciparum malaria).

2 or (cutaneous leishmaniasis), and Plasmodium falciparum (malaria).

3 opment of coma and lactic acidosis in severe falciparum malaria.

4 nsidered for rescue treatment for Plasmodium falciparum malaria.

5 ren from severe and uncomplicated Plasmodium falciparum malaria.

6 ms that confer the lower susceptibility to P.falciparum malaria.

7 acious treatment of uncomplicated Plasmodium falciparum malaria.

8 fectively treating drug-resistant Plasmodium falciparum malaria.

9 ts aged 6 months to 12 years with Plasmodium falciparum malaria.

10 besity, is associated with severe Plasmodium falciparum malaria.

11 sults of PCR for the detection of Plasmodium falciparum malaria.

12 opoietin-2, and microvascular dysfunction in falciparum malaria.

13 oscopy or rapid test confirmed uncomplicated falciparum malaria.

14 umefantrine for treatment of uncomplicated P falciparum malaria.

15 T) is the first-line treatment of Plasmodium falciparum malaria.

16 e and transmission of multidrug-resistant P. falciparum malaria.

17 nsidered for rescue treatment for Plasmodium falciparum malaria.

18 during, and after infection with Plasmodium falciparum malaria.

19 is a strong predictor of mortality in severe falciparum malaria.

20 ll of whom required treatment for Plasmodium falciparum malaria.

21 survival among children hospitalised with P falciparum malaria.

22 eduction in deaths resulting from Plasmodium falciparum malaria.

23 disease severity in Tanzanian children with falciparum malaria.

24 um vivax parasitaemia following treatment of falciparum malaria.

25 the modulating the pathogenesis of severe P falciparum malaria.

26 fication of antiadhesion drug candidates for falciparum malaria.

27 ariants protect African children from severe falciparum malaria.

28 nt against confirmed or suspected Plasmodium falciparum malaria.

29 pecificity to microscopy in patients with P. falciparum malaria.

30 h among children admitted to hospital with P falciparum malaria.

31 eans to interrupt transmission of Plasmodium falciparum malaria.

32 1 with severe malaria) presenting with acute falciparum malaria.

33 s threat to the global control of Plasmodium falciparum malaria.

34 artile range, 0.78 to 1.07) in those with P. falciparum malaria.

35 or the treatment of uncomplicated Plasmodium falciparum malaria.

36 for gametocyte clearance and for safety in P falciparum malaria.

37 on of primaquine to limit transmission of P. falciparum malaria.

38 (DP), are recommended to treat uncomplicated falciparum malaria.

39 y period, none had an episode of clinical P. falciparum malaria.

40 accompanied by effective measures to prevent falciparum malaria.

41 unate in the treatment of adults with severe falciparum malaria.

42 iparum malaria and 15 with moderately severe falciparum malaria.

43 in adults with uncomplicated P. vivax or P. falciparum malaria.

44 een associated with protection from clinical falciparum malaria.

45 ontribute to the endothelial pathology of P. falciparum malaria.

46 n-blocking vaccines (TBV) against Plasmodium falciparum malaria.

47 and maintenance of antigenic diversity in P. falciparum malaria.

48 d children with microscopically confirmed P. falciparum malaria.

49 a component of a multivalent vaccine for P. falciparum malaria.

50 re central to the pathogenesis of Plasmodium falciparum malaria.

51 that aim to control and ultimately eliminate falciparum malaria.

52 deployment in the control and eradication of falciparum malaria.

53 s the first-line treatment for uncomplicated falciparum malaria.

54 ent-based intervention strategies against P. falciparum malaria.

55 t known, nor their role in early anemia from falciparum malaria.

56 can children with cerebral and uncomplicated falciparum malaria.

57 the microvascular pathophysiology of severe falciparum malaria.

58 has one of the largest global burdens of P. falciparum malaria.

59 ulation most severely affected by Plasmodium falciparum malaria.

60 ase may contribute to pathogenesis in severe falciparum malaria.

61 nesis of life-threatening acidosis in severe falciparum malaria.

62 t mediators of protection against Plasmodium falciparum malaria.

63 e severity in imported P. falciparum and non-falciparum malaria.

64 anism of cross-species immune recognition to falciparum malaria.

65 iated with a reduced risk of death in severe falciparum malaria.

66 ributing to acidosis in patients with severe falciparum malaria.

67 ramatically reduced the burden of Plasmodium falciparum malaria.

68 e disease and a fatal outcome in adults with falciparum malaria.

69 sequestration in postcapillary venules in P. falciparum malaria.

70 patients presenting to the hospital with P. falciparum malaria (0.53% [100/18,965] versus 0.32% [57/

71 elevated in 29 Indonesian adults with severe falciparum malaria (10%; 95% confidence interval [CI], 8

72 licated P. vivax malaria (10 patients) or P. falciparum malaria (11).

73 bican children with uncomplicated Plasmodium falciparum malaria 7 days after combination treatment wi

74 In keeping with findings in children with P falciparum malaria, acute endothelial cell activation wa

75 d complete return of chloroquine-susceptible falciparum malaria after chloroquine was withdrawn from

76 aged 2-65 years, with acute, uncomplicated P falciparum malaria alone or mixed with non-falciparum sp

77 r border has led to a sustained reduction in falciparum malaria, although antimalarial efficacy has d

78 Plasmodium falciparum malaria, an infectious disease caused by a pa

79 study of 996 children with severe Plasmodium falciparum malaria and 1220 community controls and genot

80 oscopy in 13 Indonesian children with severe falciparum malaria and 15 with moderately severe falcipa

81 y lower proportionate morbidity ratios for P falciparum malaria and also for acute hepatitis and HIV/

82 Coinfection with Plasmodium falciparum malaria and Epstein-Barr virus (EBV) is a maj

83 Amino acid derangements are common in severe falciparum malaria and have been associated with endothe

84 ples from patients with confirmed Plasmodium falciparum malaria and in human whole-blood specimens st

85 cardiac function and volume status in severe falciparum malaria and its prognostic significance.

86 way for the origin and evolution of human P. falciparum malaria and may inform molecular surveillance

87 children aged 1-10 years with uncomplicated falciparum malaria and normal G6PD enzyme function to re

88 ate that neutrophil dysfunction occurs in P. falciparum malaria and support the relevance of the mech

89 The role of the glycocalyx in falciparum malaria and the association with disease seve

90 vides new knowledge regarding immunity to P. falciparum malaria and underpins efforts to develop PfEM

91 ress (238 with pneumonia, 41 with Plasmodium falciparum malaria, and 14 with both).

92 ria, severe (n = 21) and nonsevere (n = 109) falciparum malaria, and healthy controls (n = 50), we me

93 hat iron deficiency anaemia protects against falciparum malaria, and that iron supplements increase s

94 In falciparum malaria, angiopoietin-2 increased with age, i

95 nuclear cells) to the liver-stage Plasmodium falciparum malaria antigen ME-TRAP.

96 its confer protection from severe Plasmodium falciparum malaria are not yet fully elucidated.

97 Protective antibodies in Plasmodium falciparum malaria are only acquired after years of repe

98 Characteristic features of Plasmodium falciparum malaria are polyclonal B cell activation and

99 as been critical for the globalization of P. falciparum malaria as parasites adapted to new vector sp

100 with severe (SM) or moderately severe (MSM) falciparum malaria, as defined by World Health Organizat

101 relatively better protection from Plasmodium falciparum malaria, as reflected by fewer symptomatic ca

102 , we recruited patients with uncomplicated P falciparum malaria at 18 hospitals and health clinics in

103 k correlated with mothers who had Plasmodium falciparum malaria at delivery.

104 e enrolled boys and men with uncomplicated P falciparum malaria at the Malaria Research and Training

105 men in the second or third trimester who had falciparum malaria (at any parasite density and regardle

106 spatiotemporal prevalence of both Plasmodium falciparum malaria-attributable and non-malarial fever i

107 Rosetting is more common in vivax than falciparum malaria, both in terms of incidence in patien

108 urrent treatment of uncomplicated Plasmodium falciparum malaria, but ACT resistance is spreading acro

109 t recommended by the WHO to treat Plasmodium falciparum malaria, but clinical resistance against them

110 ide (NO) bioavailability characterize severe falciparum malaria, but have not been assessed in severe

111 is known to be protective against Plasmodium falciparum malaria, but it is unclear when during the co

112 eved to confer protection against Plasmodium falciparum malaria, but the precise nature of the protec

113 t efficacy of the vaccine against Plasmodium falciparum malaria, but was not powered to assess mortal

114 too weak to accurately enumerate Plasmodium falciparum malaria cases.

115 in 2010; examples were increased Plasmodium falciparum malaria (chi(2)=37.57, p<0.001); increased de

116 malaria (UM; n = 61), children with cerebral falciparum malaria (CM; n = 45), and healthy children (H

117 with Epstein-Barr virus (EBV) and Plasmodium falciparum malaria coinfections.

118 l known to protect against severe Plasmodium falciparum malaria, conclusive evidence on their role ag

119 PS antibodies are higher in vivax than falciparum malaria, correlate inversely with hemoglobin,

120 Case fatality rates in severe falciparum malaria depend on the pattern and degree of v

121 Successful control of falciparum malaria depends greatly on treatment with art

122 P falciparum malaria detected and treated during pregnancy

123 Plasmodium falciparum malaria detected at delivery in peripheral sa

124 In Plasmodium falciparum malaria, determination of which cells and pat

125 as first-line agents to treat uncomplicated falciparum malaria due to their activity against multidr

126 s MMc and that MMc alters risk of Plasmodium falciparum malaria during infancy.

127 malarials available, are not recommended for falciparum malaria during the first trimester of pregnan

128 ma IgG in adults and children living in a P. falciparum malaria-endemic area in West Africa.

129 HbS) - known to protect carriers from severe falciparum malaria - enhance parasite passage to mosquit

130 d clinical variables in patients with severe falciparum malaria enrolled in clinical trials and their

131 tment-seeking behaviour, the incidence of P. falciparum malaria fell from 511 to 249 per 1,000 person

132 We report a case of severe falciparum malaria following nosocomial Plasmodium falci

133 adults (n = 3,405, 12-87 years) with severe falciparum malaria from 15 countries in Africa and Asia

134 children aged 6-59 months with uncomplicated falciparum malaria from 3 health centers in 2013-2014 an

135 Elimination of falciparum malaria from this region should be accelerate

136 hy participants, patients with uncomplicated falciparum malaria had shorter QT intervals (-61.77 mill

137 Vaccine development in human Plasmodium falciparum malaria has been hampered by the exceptionall

138 Artemisinin-resistant falciparum malaria has emerged in Southeast Asia, posing

139 ations that confer artemisinin resistance in falciparum malaria have multiple independent origins acr

140 In a cohort of patients with falciparum malaria hospitalized in Chittagong, Banglades

141 able to confer protection against Plasmodium falciparum malaria; however, a technology for formulatin

142 e revolutionized the treatment of Plasmodium falciparum malaria; however, resistance threatens to und

143 Plasmodium falciparum malaria importation from Africa to China is r

144 or mortality found in the rising rates of P. falciparum malaria importation to China can serve to ref

145 We treated P. falciparum malaria in 215 Malian children aged 0.5-15 ye

146 um or severe malaria in 267 (86%) and non-P. falciparum malaria in 43 (14%).

147 arative analysis of treatment regimen for P. falciparum malaria in adults in Stockholm during 2000-20

148 been shown to be safe and effective against falciparum malaria in Africa and to have pronounced game

149 recommended drug regimens for uncomplicated falciparum malaria in Africa.

150 dults and children with acute, uncomplicated falciparum malaria in an open-label trial at 15 sites in

151 -RON2L) induces better protection against P. falciparum malaria in Aotus monkeys.

152 children aged 6-59 months with uncomplicated falciparum malaria in Burkina Faso.

153 apy (ACT) for multidrug-resistant Plasmodium falciparum malaria in Cambodia because of few remaining

154 likely contributes to NO bioinsufficiency in falciparum malaria in children.

155 the hypoargininemia and NO insufficiency in falciparum malaria in children.

156 2885 patients (23.8%) treated for Plasmodium falciparum malaria in clinical studies in Myanmar or on

157 ug efficacy in patients with uncomplicated P falciparum malaria in countries co-endemic for P vivax.

158 laria test (UMT) for diagnosis of Plasmodium falciparum malaria in febrile patients.

159 to the resistance it provides to Plasmodium falciparum malaria in its heterozygous state, called sic

160 reasing, creating a problem for diagnosis of falciparum malaria in locations without quality-assured

161 essfully reduced the incidence of Plasmodium falciparum malaria in many areas, there has been a consi

162 ded for the treatment of acute uncomplicated falciparum malaria in many malaria-endemic countries.

163 e hypothesized to protect against Plasmodium falciparum malaria in part by enhancing naturally-acquir

164 to AL for the treatment of uncomplicated P. falciparum malaria in pediatric patients.

165 The association between P falciparum malaria in pregnancy and stillbirth was two t

166 demic sub-Saharan Africa are attributed to P falciparum malaria in pregnancy; the population attribut

167 MAS3 in 1005 patients with uncomplicated P. falciparum malaria in relation to molecular markers of r

168 -line treatment for uncomplicated Plasmodium falciparum malaria in response to failing SP efficacy.

169 g and other interventions against Plasmodium falciparum malaria in seasonal settings in Africa.

170 s been described in patients with Plasmodium falciparum malaria in southeast Asia.

171 ug artesunate improves parasite clearance in falciparum malaria in the 2 regions.

172 Accelerated elimination of P falciparum malaria in this region is needed urgently, to

173 atients aged 2-65 years with uncomplicated P falciparum malaria in three Cambodian provinces: Pursat,

174 The prevalence of P. falciparum malaria in transfused blood was 4.7% (21/445)

175 mergence of artemisinin-resistant Plasmodium falciparum malaria in western Cambodia could threaten pr

176 The burden of anemia attributable to non-falciparum malarias in regions with Plasmodium co-endemi

177 artemisinin-piperaquine (DP) MDA in reducing falciparum malaria incidence and prevalence in 16 remote

178 ated, and safe treatments of uncomplicated P falciparum malaria, including in areas with artemisinin

179 evalence of artemisinin-resistant Plasmodium falciparum malaria increases in the Greater Mekong subre

180 a severe clinical complication of Plasmodium falciparum malaria infection and is characterized by a h

181 The RTS,S/AS01 vaccine against Plasmodium falciparum malaria infection completed phase III trials

182 e rapid and accurate diagnosis of Plasmodium falciparum malaria infection is an essential factor in m

183 Plasmodium falciparum malaria infection is associated with an early

184 Best-fit models of Plasmodium falciparum malaria infection prevalence among humans wer

185 ctive treatment for uncomplicated Plasmodium falciparum malaria infection.

186 load and the clinical severity of Plasmodium falciparum malaria infections.

187 g effectiveness" in artemisinin resistant P. falciparum malaria infections.

188 Plasmodium falciparum malaria is a deadly infectious disease in whi

189 Severe Plasmodium falciparum malaria is a major cause of death in children

190 Severe falciparum malaria is a medical emergency characterised

191 Artemisinin resistant falciparum malaria is an increasing problem in Southeast

192 Acidosis in severe Plasmodium falciparum malaria is associated with high mortality, ye

193 Artemisinin resistance in falciparum malaria is associated with kelch13 propeller

194 P. falciparum malaria is associated with systemic complemen

195 Much of the virulence of Plasmodium falciparum malaria is caused by cytoadherence of infecte

196 Cerebral Plasmodium falciparum malaria is characterized by adhesion of infec

197 s important for understanding how Plasmodium falciparum malaria is controlled.

198 A hallmark of P. falciparum malaria is extensive remodeling of host eryth

199 Although the burden of Plasmodium falciparum malaria is gradually declining in many parts

200 Immunity to Plasmodium falciparum malaria is naturally acquired in individuals

201 e-induced immunity to blood-stage Plasmodium falciparum malaria is of long-standing interest.

202 administration for elimination of Plasmodium falciparum malaria is recommended by WHO in some setting

203 Today, P. falciparum malaria is transmitted worldwide by more than

204 Plasmodium falciparum malaria is widespread in the tropical and sub

205 d accuracy of our software on 245 Plasmodium falciparum malaria isolates from three continents.

206 comparison, only 19 of 5076 patients with P. falciparum malaria (<1%) who were treated with oral arte

207 ese data show that hypoargininemia during P. falciparum malaria may altogether impair NO production a

208 plication during and after acute bouts of P. falciparum malaria may be due, at least in part, to ongo

209 sed combination therapy (ACT) for Plasmodium falciparum malaria may be threatened by parasites with r

210 tidylserine (PS) antibodies generated during falciparum malaria mediate phagocytosis of uninfected re

211 ife-threatening diseases, such as Plasmodium falciparum malaria, melioidosis, and African trypanosomi

212 t the first global, high-resolution map of P falciparum malaria mortality and the first global preval

213 acterize circulating acids in adults with P. falciparum malaria (n = 107) and healthy controls (n = 4

214 n with moderately severe (n = 77) and severe falciparum malaria (n = 129) had significantly higher mo

215 with severe (N = 101) or acute uncomplicated falciparum malaria (N = 83) were recruited from 2 hospit

216 multidrug-resistant co-lineage of Plasmodium falciparum malaria, named KEL1/PLA1, spread across Cambo

217 In falciparum malaria, neutrophil activation and NET counts

218 Patients aged >/=5 years with uncomplicated falciparum malaria, normal glucose-6-phosphate dehydroge

219 sma is a useful method for diagnosing severe falciparum malaria on fresh or archived plasma samples.

220 hese tests do not detect infections with non-falciparum malaria or Pfhrp2- and Pfhrp3-deleted P. falc

221 Plasmodium falciparum malaria originated in Africa and became globa

222 P. falciparum malaria originated in Africa from a single ho

223 MDA reduced the incidence and prevalence of falciparum malaria over a 1-year period in areas affecte

224 larial resistance has enabled the Plasmodium falciparum malaria parasite to inflict high morbidity an

225 associated with infection by the Plasmodium falciparum malaria parasite.

226 5a and 5c showed activity against Plasmodium falciparum malaria parasites (IC50 approximately 1 muM).

227 Accordingly, Plasmodium falciparum malaria parasites can be killed by small-mole

228 Plasmodium falciparum malaria parasites export the protein PfEMP1 t

229 Plasmodium falciparum malaria parasites invade and remodel human re

230 Transmission of Plasmodium falciparum malaria parasites occurs when nocturnal Anoph

231 isk of vivax parasitaemia after treatment of falciparum malaria, particularly in areas with short rel

232 ntigens play an important role in Plasmodium falciparum malaria pathogenesis and in immune evasion by

233 Retinal changes provide insights into falciparum malaria pathogenesis but have not been studie

234 single-cell genome sequences from fifteen P. falciparum malaria patients from Chikhwawa, Malawi-an ar

235 An increase of 10% in P. falciparum malaria prevalence is associated with an incr

236 empirically fitted downward time trend in P falciparum malaria prevalence over the course of the stu

237 In vivax and falciparum malaria, PS IgM and IgG on admission correlat

238 ht Bangladeshi and Indian adults with severe falciparum malaria received crystalloid resuscitation gu

239 Plasmodium falciparum malaria remains a devastating public health p

240 Plasmodium falciparum malaria remains a global public health threat

241 Plasmodium falciparum malaria remains a leading cause of childhood

242 Severe Plasmodium falciparum malaria remains a leading cause of mortality,

243 Plasmodium falciparum malaria remains a major cause of illness and

244 Plasmodium falciparum malaria remains a major public health threat

245 gan dysfunction and tissue hypoxia in severe falciparum malaria result from an imbalance between oxyg

246 t prognostic indicator in adults with severe falciparum malaria--results from sequestration of parasi

247 hreshold criteria for a definition of severe falciparum malaria should be reconsidered.

248 impaired in children and adults with severe falciparum malaria (SM).

249 )C(6) and (15)N(4) to 8 children with severe falciparum malaria (SM; age range, 4 to 9 years) and 7 h

250 Monoinfections with non-falciparum malaria species comprised <1% of the total ma

251 ia correlates with the development of severe falciparum malaria, suggesting that platelets either con

252 y acquired protective immunity to Plasmodium falciparum malaria takes years to develop.

253 remaining safe and effective treatments for falciparum malaria that can be deployed rapidly in the G

254 ted to identify studies on severe Plasmodium falciparum malaria that included information on treatmen

255 rker of artemisinin resistance in Plasmodium falciparum malaria that threatens the long-term clinical

256 P. vivax parasitaemia after treatment of P. falciparum malaria that varied significantly between stu

257 ciency and severe and complicated Plasmodium falciparum malaria through a case-control study of 2220

258 Emergence of CQ drug-resistant Plasmodium falciparum malaria throughout endemic areas of the world

259 gence and spread of resistance in Plasmodium falciparum malaria to artemisinin combination therapies

260 ical model of the transmission of Plasmodium falciparum malaria to explore the potential effect on ca

261 py, might prevent transmission of Plasmodium falciparum malaria to mosquitoes.

262 Using a mathematical model of P. falciparum malaria transmission and RTS,S vaccine impact

263 elimination project to interrupt Plasmodium falciparum malaria transmission in a rural district of s

264 safe and efficacious for the prevention of P falciparum malaria transmission in boys and men who are

265 has been seen with reductions in Plasmodium falciparum malaria transmission in some parts of Africa.

266 experienced a dramatic decline in Plasmodium falciparum malaria transmission in the past decade and i

267 We provide data showing that P. falciparum malaria transmission is heterogeneous in time

268 vidual based, spatially explicit model of P. falciparum malaria transmission that includes all the pr

269 identified efficacy studies of uncomplicated falciparum malaria treated with ACT that were undertaken

270 hanaian and Gabonese children with severe P. falciparum malaria treated with parenteral artesunate fo

271 ion of late-stage parasites in uncomplicated falciparum malaria treated with quinine.

272 a-regression analysis of cure rates from all falciparum malaria treatment trials (n = 40) with monoth

273 from British soldiers in Palestine, epidemic falciparum malaria triggered a smaller epidemic of P viv

274 ine synthesis in children with uncomplicated falciparum malaria (UM; n = 61), children with cerebral

275 In severe falciparum malaria, unlike sepsis, hypotension on admiss

276 mosquito, which is the vector for Plasmodium falciparum malaria, uses a series of olfactory cues eman

277 individual subjects infected with Plasmodium falciparum malaria, using only data obtained at the time

278 The development of an efficacious Plasmodium falciparum malaria vaccine remains a top priority for gl

279 ental pathological process underlying lethal falciparum malaria was microvascular obstruction.

280 The burden of P. falciparum malaria was reduced to a greater extent than

281 Factors associated with severe P. falciparum malaria were age <5 years and >40 years, orig

282 am infection and 35 children with Plasmodium falciparum malaria were analyzed using protein microarra

283 children aged 6-59 months with uncomplicated falciparum malaria were assigned treatment with AL or DH

284 n Thailand, parasites from 101 patients with falciparum malaria were genotyped for antimalarial drug

285 ge, 6 months to 10 years) with uncomplicated falciparum malaria were randomized to artemether-lumefan

286 and (2009-2010), patients with uncomplicated falciparum malaria were randomized to oral artesunate 6

287 Adults with Plasmodium falciparum malaria were randomized to receive 1 of 3 art

288 and Jan 18, 2018, 539 patients with acute P falciparum malaria were screened for eligibility, 292 we

289 A total of 286 patients with falciparum malaria were studied, of whom 224 had severe

290 Reads from Plasmodium falciparum (malaria) were detected in 21 patients, of wh

291 ntrasts with the retinopathy of severe adult falciparum malaria with and without coma, suggesting tha

292 were treated for 249 episodes of Plasmodium falciparum malaria with artemether-lumefantrine.

293 pre-erythrocytic) prophylaxis of Plasmodium falciparum malaria with prolonged activity would substan

294 nin-piperaquine treatment of uncomplicated P falciparum malaria, with and without the addition of pri

295 tes play a major role in the pathogenesis of falciparum malaria, with microvascular dysfunction and p

296 GCX breakdown is increased in children with falciparum malaria, with similar elevations in CM and UM

297 ce of climate on the incidence of Plasmodium falciparum malaria worldwide and how it might impact loc

298 ended treatment for uncomplicated Plasmodium falciparum malaria worldwide.

299 A common treatment for both vivax and falciparum malaria would be welcome.

300 as, children suffer the most from Plasmodium falciparum malaria, yet newborns and young infants expre